Veterans Affairs

Dexlansoprazole, the R-enantiomer of lansoprazole, is the sixth proton pump inhibitor (PPI) marketed in the U.S. for the healing and maintenance of erosive esophagitis and the fifth PPI to be approved by the Food and Drug Administration (FDA) for symptomatic treatment of nonerosive gastroesophageal reflux disease (GERD). ................
................

In order to avoid copyright disputes, this page is only a partial summary.